Recently, the tumor mutational burden (TMB) has emerged as a predictive biomarker of ICI effectiveness.26 While a large‐scale clinical trial has shown that the TMB has a role in NSCLC,27 ALK‐positive patients have a relatively low TMB.28 In addition, Gainor et al. 22 reported low rates of concurrent PD‐L1 expression and CD8+ tumor infiltrating lymphocytes within the tumor microenvironment of ALK‐positive NSCLC. The gene discussed is ALK; the disease is neoplasm.